Pipeline Products
Innovative and broad pipeline built from experience in formulation development and drug delivery
TKD-004 is a dry powder nasal drug using Therakind’s proprietary DriDose® technology. The fast-acting and easily administrable peptide product is intended for use during hypoglycaemic episodes. The candidate has gone through preclinical and clinical proof-of-concept studies.
TKD-006 is a dry powder nasal drug using Therakind’s proprietary DriDose® technology. This is a small molecule candidate for fast relief from neurodegenerative disease symptoms.
TKD-10 is a dry powder nasal drug using Therakind’s proprietary DriDose® technology.
This is a small molecule candidate to manage nausea and vomiting symptoms.
TKD-008 is a novel candidate for antimicrobial treatment. This product is being developed in collaboration with the Karolinska Institute (Iovino Group).
Contact us to discuss partnership opportunities
TKD-004 is a dry powder nasal drug using Therakind’s proprietary DriDose® technology. The fast-acting and easily administrable peptide product is intended for use during hypoglycaemic episodes. The candidate has gone through preclinical and clinical proof-of-concept studies.
TKD-005 is a dry powder nasal drug using Therakind’s proprietary DriDose® technology. This is a novel thermostable vaccine for easy storage and distribution in LMICs, and convenient administration.
TKD-006 is a dry powder nasal drug using Therakind’s proprietary DriDose® technology. This is a small molecule candidate for fast relief from neurodegenerative disease symptoms.
TKD-007 is a dry powder nasal drug using Therakind’s proprietary DriDose® technology. This is a preventative measure against cold and flu viruses.
TKD-008 is a novel candidate for antimicrobial treatment. This product is being developed in collaboration with the Karolinska Institute (Iovino Group).